Ahmad Haidar

artificial pancreas in adults and pediatric populations have shown significant improvement in reducing the incidence of the dangerously low glucose levels compared to conventional therapy, and out-patient trials are currently being conducted. The artificial pancreas is considered the most promising therapy for type 1 diabetes and its development is eagerly followed by the patients and the media. Dr. Haidar also worked on applying Bayesian modeling techniques combined with isotope tracer methodologies to investigate the pharmacokinetics and the pharmacodynamics of insulin and glucagon, and the absorption patterns of different meals in pediatrics with type 1 diabetes as well as pregnancy. In 2013, Dr. Hairdar received the McGill University William and Rhea Seath Award in Engineering Innovation, the IRCM André-Barbeau Excellence Award, and the Juvenile Diabetes Research Foundation Postdoctoral award. In 2014, Dr. Haidar was awarded the prestigious Banting Postdoctoral Fellowship.